Reported by TechCrunch •
20 Public broadcaster L R No clear lean ✓ verified
Why this rating? · 4 signals

Signals flagged in the original

  • loaded language: 'reeling'
  • loaded language: 'post-pandemic crash'
  • loaded language: 'blockbuster drugs'
  • framing: The headline foregrounds Jobs's famous surname rather than the venture firm's business, but does not assert a political or evaluative conclusion.

Analyzed by our bias model Full breakdown ↓

Reed Jobs discusses advancements at Yosemite and the role of AI in biotech

Reed Jobs spoke about the progress of his biotech venture firm, Yosemite, which has expanded to a team of 17. He mentioned the upcoming loss of patent protection for several drugs and the growing role of artificial intelligence in the firm's work.

Companies
Yosemite
People
Reed Jobs

Our neutral summary

Reed Jobs spoke about the progress of his biotech venture firm, Yosemite, which has expanded to a team of 17. He mentioned the upcoming loss of patent protection for several drugs and the growing role of artificial intelligence in the firm's work.

Read the full story at TechCrunch

The reporting belongs to TechCrunch; we don't reproduce it.

Annotating as

No note attached

on this article.

Language Analysis

Loaded-language score 20/100
wirepublicmainstream flavoredpartisanadvocacy
Inflammatory language 41/100
Sentiment +50/100

Loaded Language Removed

  • ✕ loaded language: 'reeling'
  • ✕ loaded language: 'post-pandemic crash'
  • ✕ loaded language: 'blockbuster drugs'
  • ✕ framing: The headline foregrounds Jobs's famous surname rather than the venture firm's business, but does not assert a political or evaluative conclusion.

Original vs. Neutral

Original Headline

Reed Jobs would rather talk about curing cancer than his last name

Neutral Headline

Reed Jobs discusses advancements at Yosemite and the role of AI in biotech